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Abstract
OBJECTIVE—To determine if umbilical cord serum concentrations of interleukin-6 (IL-6), C-
reactive protein (CRP), and myeloperoxidase (MPO), in pregnancies at risk for preterm birth 
(PTB), are associated with neonatal morbidities and/or altered neurodevelopmental outcomes in 
the children.
STUDY DESIGN—Umbilical cord serum samples were collected at birth from 400 newborns 
delivered within a multicenter randomized controlled trial of repeated versus single course of 
antenatal corticosteroids (ACs), in women at increased risk for PTB. Newborns were followed 
through discharge and were evaluated between 36 and 42 months corrected age with neurological 
examination and Bayley Scales of Infant Development. Umbilical cord serum concentrations of 
IL-6, CRP, and MPO were determined using enzyme-linked immunoassays. Multivariate logistic 
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regression analyses explored the relationship between umbilical cord serum IL-6, CRP and MPO 
levels, adverse newborn outcomes and PTB < 32 weeks of gestational age (GA).
RESULTS—Univariate analysis revealed that umbilical cord IL-6 above the 75th percentile was 
associated with increased respiratory distress syndrome (RDS) and chronic lung disease (CLD), 
but not with necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), or neonatal 
sepsis; however, this association was not significant after adjusting for gestational age at delivery 
and treatment group. No significant associations between CRP or MPO, and RDS, CLD, NEC, 
sepsis or IVH were evident. Regression analysis revealed that CRP above the 75th percentile was 
associated with a decreased risk of CLD (O.R. 0.10, 95% C.I. 0.02–0.41). No associations 
between umbilical cord IL-6, CRP or MPO, and MDI < 70 or PDI < 70 were evident. Umbilical 
cord serum IL-6, CRP, and MPO, above the 75th percentile, were associated with more frequent 
PTB < 32 weeks GA.
CONCLUSION—Elevated umbilical cord serum concentration of CRP is associated with 
reduced risk for CLD even after adjusting for gestational age at delivery. Occurrence of levels > 
75th percentile of IL-6, CRP, and MPO in umbilical cord serum were associated with PTB < 32 
weeks GA. Elevated umbilical cord serum concentrations of IL-6, CRP, and MPO at birth were 
not associated with poor neurodevelopmental outcomes.
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INTRODUCTION
Subclinical intrauterine infection and/or inflammation is thought to account for 25–40% of 
preterm birth (PTB).1–2 Fetuses exposed to intraamniotic infection and/or inflammation are 
at increased risk for pulmonary and neurological damage, and neonatal and infant 
morbidities, including respiratory distress syndrome (RDS)3 bronchopulmonary dysplasia 
(BPD)4–6 sepsis,3,7,8 necrotizing enterocolitis (NEC)7–9 intraventricular hemorrhage 
(IVH),10–11 periventricular leukomalacia (PVL)9–10,12–13 and cerebral palsy (CP).14 The 
most advanced, and serious, stage of ascending intrauterine infection is fetal infection. 
Pregnancies with the fetal inflammatory response syndrome (FIRS), defined as elevated 
concentrations of interleukin-6 (IL-6) in fetal plasma3 are at increased risk for severe 
neonatal morbidities (RDS, neonatal sepsis, pneumonia, BPD, IVH, PVL or NEC.3 
Neonates with funisitis, a histological hallmark of FIRS,15 are at increased risk for neonatal 
sepsis,16 BPD 6 and CP.14
Inflammatory mediators play a role in the mechanism of preterm parturition, and pulmonary 
and neurological injury. Cytokines mediate acute lung injury,17 exacerbate ventilator-
associated lung injury,18 and modulate host defenses.19 Increased cytokine concentrations 
are observed in tracheal aspirates20–21 and serum22–23 of infants with RDS who 
subsequently develop BPD. The process responsible for neurological damage that leads to 
some cases of PVL and CP begins in utero, and is related to exposure to intraamniotic 
inflammation.24–25 Intrauterine infections instigate activation of the maternal and fetal 
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cytokine networks that leads to PTB and also white matter damage in the neonatal 
brain.24–25 Increased cytokine concentrations in the amniotic fluid4,10,14 and umbilical cord 
blood12,26 of preterm infants have been associated with PVL4,10,12,26 and CP.14,26
There is a paucity of data concerning the association between umbilical cord serum 
concentrations of IL-6, CRP, and MPO at birth, and neonatal morbidities, and long term 
neurodevelopmental morbidities in children of women identified during pregnancy to be at 
increased risk for PTB.
The purpose of this study was to examine whether umbilical cord serum concentrations at 
birth of IL-6, CRP, and MPO, in pregnancies that were at risk for PTB, are markers for 




This is a secondary analysis utilizing data and umbilical cord serum samples collected 
during a randomized, double-masked, placebo-controlled, multicenter clinical trial of 
repeated versus a single course of antenatal corticosteroids (ACs), and data from long-term 
follow-up of the children. The primary trial was performed at 18 centers of the Eunice 
Kennedy Shriver National Institutes of Child Health and Human Development (NICHD) 
Maternal-Fetal Medicine Units (MFMU) Network. Recruitment took place from March 
2000 to April 2003. The overall study population and methods for this trial have previously 
been described.27 Follow-up examinations were performed between July 2002 and May 
2006, and results of the long-term follow-up of children enrolled in the randomized trial 
have been previously described.28 The original clinical trial and follow-up study of children 
were approved by the institutional review boards at all participating centers, and informed 
consent was obtained from all participants. The institutional review board of Wayne State 
University School of Medicine approved the secondary analysis described here.
Patient population and data collection
Pregnant women with intact membranes between 23 weeks and 0 days and 31 weeks 6 days 
GA who had received one course of AC 7 to 10 days earlier, and were at increased risk for 
spontaneous PTB were randomized to receive additional weekly courses of betamethasone 
or identical-appearing placebo. Exclusion criteria were insulin-dependent diabetes mellitus, 
systemic corticosteroid use during pregnancy, clinical diagnosis of chorioamnionitis, non-
reassuring fetal status, preterm rupture of membranes, or a major fetal anomaly. The first 67 
enrolled women received weekly repeat courses of betamethasone until 33 6/7 weeks’ GA. 
Subsequently the number of repeat courses was limited to four. Maternal, clinical, and 
demographic data were collected at the time of randomization, delivery, and discharge.
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A sample of mixed umbilical cord blood was collected from the umbilical cord at birth. 
After clot formation at room temperature, the sample was centrifuged for 10 minutes at 3400 
rpm; the serum was divided into aliquots, frozen, and stored for future batch analysis.
Newborn data and outcomes
Newborns were followed until either discharge from the hospital, or up to 120 days, at 
which time relevant data from the nursery records were obtained. Cranial ultrasounds were 
performed by 14 days of age on all infants for the occurrence of IVH, PVL, and were read 
centrally by masked reviewers. RDS was defined as requiring oxygen from 6 to 24 hours of 
age, clinical features of RDS within 24 hours of age, respiratory support from 6 to 24 hours 
of age, and an abnormal X-ray within 24 hours of age. CLD was defined as the need for 
supplemental oxygen at 36 weeks’ corrected age in infants born before 34 weeks GA. The 
diagnosis of sepsis required a clinically ill infant in whom systemic infection was suspected 
with a positive blood, cerebrospinal fluid, or catheterized/suprapubic urine culture, or in the 
absence of positive cultures, with clinical evidence of cardiovascular collapse, or an 
unequivocal X-ray confirming infection.
Evaluation of children
The cohort of enrolled women was contacted by the study personnel at least every 3 months. 
The children were to return for evaluation when they were between 24 and 35 months of 
age, corrected for gestational age at birth, for a detailed medical history, evaluation of 
developmental milestones, physical and neurological examination, and measurement of 
Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI) scores 
from the Bayley Scales of Infant Development, second edition. Centrally trained and 
certified study personnel, who were unaware of treatment assignment, performed the follow-
up examinations using a standardized protocol. Neurological examinations were performed 
by pediatricians or pediatric neurologists. The Bayley MDI and PDI scores were determined 
by trained study psychologists or psychometrists and calculated on the basis of corrected 
age. Children who returned for evaluation when they were between 36 and 42 months of 
corrected age were included and underwent both physical and Bayley assessments.
IL-6, CRP, and MPO Immunoassays
Highly sensitive enzyme-linked immunoassays were used to determine concentrations of 
IL-6 (R&D Systems [Minneapolis, MN]), CRP and MPO (ALPCO Diagnostics [Salem, 
NH]) in umbilical cord vein serum samples. Serum was incubated in duplicate in micro titer 
plates which had been pre-coated with antigen specific (IL-6, CRP, or MPO) monoclonal 
antibodies. The concentrations of IL-6, CRP or MPO in umbilical cord serum samples were 
determined by interpolation from individual standard curves composed of human IL-6, CRP 
or MPO. The calculated inter-assay and intra-assay coefficients of variation (CV) for IL-6, 
CRP and MPO immunoassays in our laboratory were 5.8%, 8.6% and 4.7% and 3.2%, 3.2% 
and 3.8%, respectively. The calculated lower limits of detection (sensitivity) for IL-6, CRP 
and MPO immunoassays were 0.14 pg/ml, 0.86 ng/ml, and 0.66 ng/ml respectively.
Sorokin et al. Page 4














The associations between umbilical cord serum concentration of IL-6, CRP, and MPO with 
rates of individual neonatal morbidities, poor neurodevelopmental outcomes (Bayley MDI 
score < 70 or Bayley PDI score < 70) at 24 to 36 months, and PTB < 32 weeks GA were 
examined. Umbilical cord serum concentrations of IL-6, CRP and MPO were dichotomized 
into high (> 75th percentile) and not high (≤ 75th percentile) groups. For PTB < 32 weeks 
GA, singletons and twins with the highest analyte concentration were included in the 
analysis and the associations between high and not high analyte concentrations and PTB < 
32 weeks GA were compared using the Chi-square test.
Multivariable logistic regression analysis was used to explore these associations while 
adjusting for possible confounders. The regression models included GA at delivery, 
treatment group, and analyte. P-values, and the unadjusted and adjusted ORs were generated 
using General Estimating Equations (GEE) Models.29 GEE regression analysis was also 
used to examine differences between treatment groups in log transformed cytokine values. 
This model was used since it accounts for correlation between twins. A nominal two-sided p 
value of less than 0.05 was considered to indicate statistical significance. Analyses were 
performed with SAS statistical software (SAS Institute Inc, Cary NC).
RESULTS
There were 495 patients randomized in the trial, 252 in the repeat AC group and 243 in the 
placebo group. There were no significant differences between the two groups in 
demographic parameters.27 There were 492 neonates with neonatal outcomes, 250 in the AC 
group and 242 in the placebo group. Four hundred and sixty-five children underwent Bayley 
examinations, 235 in the AC group and 230 in the placebo group.
Umbilical cord serum samples were collected at birth from 400 newborns (GA: 34.8 +/− 3.8 
weeks). Umbilical cord serum concentrations of IL-6, CRP, and MPO were not significantly 
different between repeat AC (treatment group) and placebo groups (Table I), but there was a 
non-significant trend for higher concentrations of CRP in the AC group.
Univariate analysis showed that umbilical cord concentrations of IL-6, above the 75th 
percentile, were associated with RDS (p=0.02) and CLD (p=0.04), but not with IVH, 
necrotizing enterocolitis or neonatal sepsis. However, this association was no longer 
significant after adjustment for GA at delivery and treatment group in the regression 
analysis. In the univariate analysis there was no significant relationship between umbilical 
cord serum concentrations of CRP and MPO, above the 75th percentile, and development of 
neonatal RDS, CLD, sepsis, neonatal enterocolitis, and IVH. Logistic regression analysis for 
each analyte indicated that umbilical cord serum concentration of CRP, but not IL-6 or 
MPO, above the 75th percentile, was significantly associated with a decreased risk of CLD 
(O.R. 0.10, 95% C.I. 0.02–0.41) even after adjusting for GA at delivery and treatment group 
(Table II). Regression analysis demonstrated no association between umbilical cord 
concentrations of IL-6, CRP and MPO, above the 75th percentile and poor 
neurodevelopmental outcomes (MDI <70 or PDI < 70) (Table III). Umbilical cord serum 
Sorokin et al. Page 5













median concentrations of IL-6, CRP, and MPO, above the 75th percentile, were associated 
with more frequent PTB < 32 weeks (Table IV).
For the subgroup of pregnancies delivered before 32 weeks of gestation, logistic regression 
analysis for each analyte demonstrated that umbilical cord serum concentration of CRP, but 
not IL-6 or MPO, above the 75th percentile, was associated with decreased risks of RDS 
(O.R. 0.27, 95% C.I. 0.08–0.95) and CLD (O.R 0.06, 95% C.I. 0.01–0.80), and increased 
risk of NEC (O.R. 5.93, 95% C.I. 1.00–35), after adjusting for GA at delivery and treatment 
group (Table V). Regression analysis demonstrated no associations between umbilical cord 
serum concentrations of IL-6, CRP, and MPO, above the 75th percentile, and MDI < 70 or 
PDI < 70 in pregnancies that delivered at < 32 weeks of gestation (Table VI). Among 
neonates that delivered at > 32 weeks of gestation there were very few with morbidies (not 
shown), not enough for statistical comparison.
DISCUSSION
Principal Findings of the Study
The results of this study suggest that in women identified to be at increased risk for PTB 
because of a prior episode of preterm labor or other risk factors, elevated umbilical cord 
serum concentrations of IL-6, CRP, and MPO were not associated with development of 
neonatal RDS, sepsis, NEC, IVH, or poor neurodevelopmental outcomes (MDI <70 or PDI 
< 70). However, an elevated umbilical cord serum concentration of CRP, but not IL-6 or 
MPO, was associated with a decreased risk of CLD, after adjusting for GA at delivery and 
treatment group. An elevated umbilical cord serum concentration of IL-6, CRP, and MPO 
was associated with PTB < 32 weeks GA. In the subgroup of women who delivered at < 32 
weeks of gestation, an elevated umbilical cord serum concentration of CRP, but not IL-6 or 
MPO, was associated with a decreased risk of RDS and CLD. Umbilical cord serum median 
concentrations of the 3 analytes were not significantly different between neonates born to 
women allocated to receive either repeat AC or placebo groups, but there was a non-
significant trend for higher concentrations of CRP in the AC group.
Interpretation of the Findings
The lack of association between the umbilical cord blood concentrations of IL-6, CRP and 
MPO and the development of neonatal RDS, sepsis, NEC, IVH or poor neurodevelopmental 
outcomes was unexpected because previous studies indicate a relationship between the risk 
of some of these complications and elevated umbilical cord concentrations of acute phase 
reactants, cytokines, and chemokines. The same is the case for the relationship between an 
elevated umbilical cord serum CRP and a decreased risk of CLD.
The association between higher concentrations of CRP, IL-6 and MPO and delivery before 
32 weeks of gestation is consistent with previous reports that the earlier gestational age at 
birth, the higher the risk of intraamniotic infection,30 intraamniotic inflammation,31 
histologic chorioamnionitis,32 funisitis, 16 and evidence of systemic FIRS.33
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IL-6, a pleiotropic proinflammatory cytokine, is a major mediator of host response to 
inflammation and infection and an early marker of the acute phase response to infection or 
tissue injury. An elevated umbilical cord serum IL-6 has been used to define the FIRS.3,34 
Many investigators have examined the relationship between umbilical cord serum 
concentration of IL-6 and neonatal, and/or infant, morbidity. The results have not been 
consistent. While some reports found a significant association between elevated umbilical 
cord serum concentrations of IL-6 and BPD, 6 CLD, 35 sepsis 7–8,36–37 NEC, 7,9 PVL, 12 and 
IVH, 7,11 in pregnancies that either delivered after PPROM, 36 or had PTB (GA range < 36 
weeks – <32 weeks),6,8–9,12,35,37 or birthweight < 1501 grams,11 other investigators found 
no association between elevated umbilical cord serum concentrations of IL-6 and IVH, 38 
PVL, 38 PDI scores, 39 MDI < 85 and/or PDI < 85, 40 or CP, 40 in pregnancies complicated 
with either PTL 39 or PTB < 32 weeks GA. 38–40 The discrepancy in results has been 
attributed to differences in study design, inclusion criteria, availability of umbilical cord 
samples, characteristics of the study population, performance features of the assay, and lack 
of control for potential confounding factors.
We expected that infection and/or inflammation in the fetal compartment would be reflected 
by an elevated umbilical cord serum IL-6 concentration in pregnancies at risk for PTB and 
especially in those that delivered <32 weeks GA. The parent study did not include analyses 
of amniotic fluid or histology of the placenta; therefore, we were unable to examine if this 
relationship occurred in this study. Nonetheless, the significantly higher concentrations of 
umbilical cord serum IL-6, among patients who delivered <32 weeks of gestation suggest 
that this may have been the case.
There are several explanations for the lack of association between Il-6 and short and long 
term morbidity. First, this study was based in a unique population, not studied before; 
pregnancies at risk for PTB, who received a dose of AC and remained undelivered for 7–10 
days. The maternal complications that confer the risks of PTB were heterogeneous, e.g. prior 
spontaneous PTB at 20–34 weeks GA, placenta previa, chronic abruption. It is possible that 
the frequency of infection/inflammation among these groups may be different and that this 
cohort was at low risk for infection by virtue of remaining pregnant long enough to be 
randomized to a second course of steroids. It is noteworthy that the mean gestational age at 
birth was 34.8 +/− 3.8 weeks. This is a relatively advanced GA at delivery, and the 
frequency and severity of intraamniotic infection/inflammation was low. This may explain 
in part the lack of association with morbidity. It is also important to note that the number of 
women who delivered before 32 weeks GA is small.
C-reactive protein
CRP is an acute-phase reactant produced by liver cells, in response to IL-6, synthesized 
during the course of tissue injury or infection. CRP concentrations have been used in 
neonatology to assess the risk of neonatal sepsis. CRP determinations are simple, well-
established, inexpensive, rapid, and widely available in most clinical laboratories to 
determine whether or not patients have evidence of a plasma acute phase response to 
infection or tissue injury. More recently investigators have used a new highly sensitive assay 
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of CRP and observed that serum CRP concentration is a predictor of risk for the 
development of atherosclerosis and coronary artery disease.41 Yoon et al12,42 found 
associations between umbilical serum concentrations of CRP and neonatal sepsis,42 and 
PVL12 in pregnancies with PTB < 36 weeks GA. In contrast, we were unable to demonstrate 
an association between umbilical cord serum concentration of CRP and either neonatal 
sepsis or PVL, but we found an association between umbilical cord serum CRP and 
decreased risk of CLD. While neonatal cord concentrations of some cytokines were found to 
be significantly increased in neonates with CLD,43 a recent study of neonatal blood 
collected from over 1000 infants, who weighed 401 to 1000 g at birth, found higher 
concentrations of some cytokines including IL-1β, IL-6, IL-8, and IL-10, as well as 
interferon γ, and lower concentrations of other cytokines such as IL-17 and tumor necrosis 
factor β associated with BPD or death.44 These investigators did not find a relationship 
between CRP concentrations and the subsequent development of BPD. Based on the results 
of multivariate analyses, the authors propose that the risk of BPD may be due to an 
impairment in the transition from the innate immune response mediated by neutrophils to the 
adaptive immune response mediated by T lymphocytes. It is important to note that these 
conclusions were based not on results of umbilical cord blood collected at the time of birth, 
but rather on neonatal blood collected within 4 hours of birth and on days 3, 7, 14 and 21 of 
life. Therefore, blood samples used in this study were obtained at a different time point and 
we do not have longitudinal observations. It is unlikely that the mothers included in the 
study by Ambalavanan are similar to that of the current report.
Our findings of the relationship between CRP in the umbilical cord and RDS and CLD, but 
not NEC, are in variance with some observational and experimental data suggesting that 
markers of antenatal infection, and presence of antenatal infection, are associated with an 
increased risk of RDS and lung disease in the neonates.45 Kramer et al45 suggest that fetal 
exposure to inflammation has both detrimental and beneficial effect on the preterm lung. In 
a recent review of new data concerning lung disease resulting from complications of very 
preterm birth, Alan Jobe concludes that recent clinical research about the association 
between antenatal infection/inflammation and RDS or BPD remains incompletely 
understood.46 Pathogenesis of CLD was first attributed to barotrauma and oxygen toxicity 
acting on immature lung tissue, but current data suggest that the main risk factors for CLD 
include gestational age at delivery, antenatal infection/inflammation, postnatal infection/
inflammation, presence and duration of mechanical ventilation and supplemental oxygen.47 
Fetal exposure to inflammation contributes to the relatively low incidence of RDS in very 
preterm infants.48–50 Chorioamnionitis decreased the incidence of BPD in unventilated 
infants, but increased the risk of BPD in ventilated preterm infants (3). In the ELGAN study 
which included over 1300 infants < 28 weeks GA, there was no correlation between 
chorioamnionitis and severity of early respiratory disease or BPD.51 Inflammation limited to 
the placenta and chorion was associated with decreased RDS, while chorioamnionitis with 
fetal involvement increased the risk of RDS in early gestational age infants.52 In a 
multicenter study, clinical chorioamnionitis was associated with an increased risk of IVH 
and early-onset sepsis, but not respiratory outcomes.53 Populations of fetuses ascertained 
with different criteria, as well as the methods used for the diagnosis of infection and/or 
inflammation, represent overlapping but distinct populations that may have different 
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outcomes. For example, in the Alabama Preterm Birth study, histologic chorioamnionitis 
was associated with a decreased frequency of RDS,54 while a positive umbilical cord blood 
culture for ureaplasma and/or mycoplasma had no effect on the frequency incidence of 
RDS.54 Interestingly, the converse was true for BPD in the same patient cohort. BPD was 
more frequent in the infants with ureaplasma/mycoplasma-positive cord blood cultures,55 
but not for the overall population of infants with histological chorioamnionitis.54 Increased 
concentration of CRP in umbilical cord serum may reflect presence of antenatal infection 
and/or inflammation, but in the current study umbilical cord blood cultures, amniotic fluid, 
or placentas were not available to ascertain the precise nature and frequency of infection 
and/or inflammation.
Animal studies suggest that the association between chorioamnionitis, RDS, and BPD are 
confounded by several factors, e.g. duration of fetal exposure, extent of fetal responses, 
severity of inflammation, and the organism inciting the inflammatory response, that are 
usually unknown in clinical research.46 These and other factors that might modify responses 
(oxygen, ventilation) or suppress responses (antenatal steroids) that contributes to the 
frequency of a specific outcome in a sub-population of fetuses.45 Simple explanations of a 
clinical or histological diagnosis of chorioamnionitis may mask populations of infants with 
either increased or decreased risks of outcomes such as RDS or BPD.46
Another potential explanation for the findings reported herein is the nature of the study 
population. The group of patients enrolled in this study is highly selective, because it 
includes women at risk for PTB who received one dose of steroids and remained 
undelivered and therefore, eligible for a second dose of steroids. This population is very 
different from the one that is the subject of observational studies in which patients admitted 
with preterm labor are observed, and there is not a preselection of patients who remain 
undelivered. Populations of fetuses with different markers of antenatal infection may have 
different RDS and CLD outcomes, partly due to the imprecise nature of the diagnoses of 
RDS and BPD.45
Effect of treatment allocation is an unlikely explanation of the results since umbilical cord 
serum concentrations of the analytes were not significantly different between repeat AC 
(treatment group) and placebo group, and in our analysis we adjusted for treatment 
allocation, and effect of treatment allocation was excluded.
Myeloperoxidase
MPO, a leukocyte activation mediator,56 is a constituent of the neurophil phagosome and 
contributes to bacterial killing. MPO has been correlated to phagocyte degranulation,57 and 
implicated in vascular regulation56 and vascular disease.58 MPO is a potential biomarker of 
PTB and subsequent inflammatory insults, and umbilical cord blood is a suitable source of 
leukocytes for examination of their adherence in the setting of inflammation. 59 Although in 
pregnancies delivered preterm elevated concentrations of MPO in umbilical cord serum 
were associated with PTB,60–61 they were not associated with CP.61 In our study population 
umbilical cord serum concentration of MPO was a marker for PTB < 32 weeks GA, but not 
a marker for neonatal and infant morbidities. The factors reviewed above for IL-6 and CRP 
apply to MPO and the results observed in the study.
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We can speculate on potential clinical implications of our findings. Pregnancies at risk for 
PTB are at increased risk for intraamniotic infection, fetal inflammatory response syndrome 
(FIRS), neonatal sepsis, and their long term consequences. The vast majority of pregnancies 
that have intraamniotic infection are asymptomatic and lack signs of clinical 
chorioamnionitis. When tocolysis is administered to patients with preterm labor concerns for 
possible fetal/neonatal harm due to prolongation of pregnancies with intraamniotic infection, 
are raised. Our findings, of lack of association between elevated umbilical cord serum 
concentration of IL-6, CRP, and MPO with poor neurodevelopmental outcomes in patients 
identified to be at risk for PTB, should be reassuring to clinicians that utilize tocolysis in 
patients with preterm labor.
Studies to date of the associations between umbilical cord concentrations of IL-6, CP and 
MPO and adverse neonatal outcome, were in pregnancies delivered preterm, and most were 
limited to short term neonatal outcomes. The few studies reporting long term outcomes have 
primarily focused on the risk of CP. In this study we report on the association with both 
short term morbidities and long term neurodevelopmental outcomes. In pregnancies 
identified to be at risk for PTB elevated umbilical cord serum concentrations of IL-6, CRP, 
and MPO were associated with PTB < 32 weeks GA, but not with poor neurodevelopmental 
outcomes.
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Table II
Logistic Regression Analysis for Elevated Umbilical Cord Analytes (IL-6, CRP and MPO) at Birth and Risk 
of Neonatal Morbidities
Analyte N Odds Ratio 95% CI P-value
RDS
 IL-6 >75th percentile 400 0.88 0.36–2.14 0.79
 CRP >75th percentile 400 0.64 0.26–1.58 0.34
 MPO >75th percentile 399 0.50 0.20–1.21 0.12
CLD
 IL-6 >75th percentile 400 0.33 0.09–1.23 0.10
 CRP >75th percentile 400 0.10 0.02–0.41 0.002
 MPO >75th percentile 399 0.55 0.15–2.07 0.38
Sepsis
 IL-6 >75th percentile 400 0.52 0.14–1.99 0.34
 CRP >75th percentile 400 1.06 0.40–2.84 0.91
 MPO >75th percentile 399 0.77 0.20–2.93 0.70
NEC
 IL-6 >75th percentile 400 1.85 0.50–6.78 0.35
 CRP >75th percentile 400 1.60 0.47–5.41 0.45
 MPO >75th percentile 399 1.25 0.38–4.14 0.72
IVH
 IL-6 >75th percentile 387 1.00 0.31–3.19 1.00
 CRP >75th percentile 387 1.22 0.45–3.33 0.69
 MPO >75th percentile 386 1.29 0.44–3.73 0.64
The logistic regression analysis model included gestational age at delivery, treatment group and analytes. CI, confidence interval; CLD, chronic 
lung disease; CRP, C-reactive protein; IL-6,
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Table III
Logistic Regression Analysis for Elevated Umbilical Cord Serum Analytes (IL-6, CRP and MPO) at Birth and 
Association with Neurodevelopmental Outcomes (MDI < 70 and PDI < 70)
Analyte N Odds Ratio 95% CI P-value
MDI < 70
 IL-6 >75th percentile 318 1.28 0.62–2.63 0.51
 CRP >75th percentile 318 0.78 0.46–1.31 0.35
 MPO >75th percentile 317 0.84 0.47–1.51 0.56
PDI < 70
 IL-6 >75th percentile 318 1.15 0.50–2.63 0.75
 CRP >75th percentile 318 0.72 0.27–1.87 0.50
 MPO >75th percentile 317 0.87 0.36–2.10 0.75
IL-6, interleukin-6; CRP, C-reactive protein; MPO, myeloperoxidase
MDI denotes Bayley II Mental Developmental Index; PDI is Bayley II Psychomotor Developmental Index.
Regression models included gestational age at delivery, treatment group, and analyte.
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Table IV
Elevated Umbilical Cord Serum Concentrations at Birth of Analytes (IL-6, CRP and MPO) and Risk of 
Preterm Birth <32 Weeks of Gestation.














Yes (> 181.5) ng/ml 32.2% (29/90)
IL-6, interleukin-6; CRP, C-reactive protein; MPO, myeloperoxidase
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Table V
Logistic Regression Analysis for Elevated Umbilical Cord Serum Analytes (IL-6, CRP and MPO) at Birth and 
Association with Neonatal Morbidities For Infants born at < 32 weeks’ GA
Analyte N Odds Ratio 95% CI P-value
RDS
 IL-6 >75th percentile 93 1.81 0.61–5.33 0.28
 CRP >75th percentile 93 0.27 0.08–0.95 0.04
 MPO >75th percentile 92 0.63 0.21–1.87 0.40
CLD
 IL-6 >75th percentile 93 0.14 0.01–1.61 0.12
 CRP >75th percentile 93 0.06 0.01–0.80 0.03
 MPO >75th percentile 92 1.04 0.22–5.06 0.96
Sepsis
 IL-6 >75th percentile 93 0.61 0.15–2.54 0.50
 CRP >75th percentile 93 1.53 0.44–5.33 0.51
 MPO >75th percentile 93 1.29 0.33–5.05 0.72
NEC
 IL-6 >75th percentile 93 0.88 0.12–6.39 0.90
 CRP >75th percentile 93 5.93 1.00–35 0.05
 MPO >75th percentile 92 2.40 0.45–12.89 0.31
IVH
 IL-6 >75th percentile 93 1.95 0.54–7.09 0.31
 CRP >75th percentile 93 0.51 0.10–2.46 0.40
 MPO >75th percentile 92 1.11 0.35–3.51 0.86
The logistic regression analysis model included gestational age at delivery, treatment group and analytes. CI, confidence interval; CLD, chronic 
lung disease; CRP, C-reactive protein; IL-6, interleukin-6; MPO, myeloperoxidase; NEC, necrotizing enterocoloitis; RDS, respiratory distress 
syndrome
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Table VI
Logistic Regression Analysis for Elevated Umbilical Cord Serum Analytes (IL-6, CRP and MPO) at Birth and 
Association with Neurodevelopmental Outcomes (MDI < 70 and PDI < 70) For Infants born at < 32 weeks’ 
GA
Analyte N Odds Ratio 95% CI P-value
MDI < 70
 IL-6 >75th percentile 71 0.91 0.27–2.99 0.87
 CRP >75th percentile 71 1.05 0.30–3.75 0.94
 MPO >75th percentile 70 1.00 0.99–1.01 0.67
PDI < 70
 IL-6 >75th percentile 71 1.76 0.52–5.96 0.37
 CRP >75th percentile 71 0.25 0.03–2.10 0.20
 MPO >75th percentile 70 1.43 0.33–6.20 0.64
-IL-6, interleukin-6; CRP, C-reactive protein; MPO, myeloperoxidase
-MDI denotes Bayley II Mental Developmental Index; PDI is Bayley II Psychomotor Developmental Index.
-Regression models included gestational age at delivery, treatment group, and analyte.
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